Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727243 | 0.88 | PKM (0.46) | KMT2AMEN1RAB9ADHFRPKM | |
| SCHEMBL3058714 | 0.86 | ALDH1A1 (0.46) | KMT2AMEN1RAB9AHPGDDHFR | |
| SCHEMBL9637065 | 0.84 | DHFR (0.45) | KMT2AMEN1RAB9AHPGDDHFR | |
| SCHEMBL25621200 | 0.84 | HPGD (0.47) | RAB9AHPGDEPHX2DHFRPKM | |
| SCHEMBL11769348 | 0.84 | HDAC6 (0.45) | KMT2AMEN1HPGDEPHX2DHFR | |
| SCHEMBL220900 | 0.84 | KMT2A (0.51) | KMT2AMEN1HPGDKMODHFR | |
| SCHEMBL3184997 | 0.81 | DHFR (0.53) | KMT2AMEN1RAB9ADHFRNPC1 | |
| SCHEMBL3237592 | 0.81 | ALDH1A1 (0.47) | KMT2AMEN1RAB9AHPGDDHFR | |
| SCHEMBL17700609 | 0.81 | HPGD (0.45) | KMT2AMEN1RAB9AHPGDDHFR | |
| SCHEMBL225085 | 0.81 | KMT2A (0.65) | KMT2AMEN1RAB9AEPHX2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | KMT2A 2740/4885MEN1 2386/4885AKR1C3 163/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | KMT2A 2740/4885MEN1 2386/4885AKR1C3 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.